Achilles Therapeutics Announces Strategic Update | Achilles ...
WEB22 hours ago · Achilles Therapeutics Announces Strategic Update. –Achilles to discontinue development of TIL-based cNeT therapy–. –Cash position of $95.1 million as of June 30, 2024–. –BofA Securities engaged to provide strategic financial advice–. LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Achilles …
Achilles drops cell therapy program, braces for layoffs
WEB9 hours ago · Achilles Therapeutics has torn up its strategy. The British biotech is stopping work on its clinical-phase cell therapy, looking into deals with groups working on other modalities and preparing to ...
Achilles Therapeutics Discontinues TIL-based CNeT Program
WEB6 hours ago · Sep. 19, 2024, 11:48 AM. (RTTNews) - Achilles Therapeutics plc (ACHL) Thursday announced the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical ...
Achilles stock climbs on strategic focus (NASDAQ:ACHL)
WEB10 hours ago · Achilles Therapeutics (ACHL) stock surges as company announces plans to explore strategic alternatives. Read more here.
Achilles Therapeutics Shares Are Trading Higher: What You
WEB22 hours ago · Shares of Achilles Therapeutics plc (NASDAQ: ACHL) are surging following a major strategic announcement from the company. The biotechnology firm revealed plans to discontinue its TIL-based cNeT ...
Achilles Therapeutics Provides Interim Phase I/IIa Update on …
WEBLONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced interim Phase I/IIa data on the use of clonal neoantigen reactive T cells (cNeT) from the CHIRON ...
Achilles Therapeutics Announces Research Collaboration with
WEBMay 22, 2024 · The research collaboration will combine Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading sa-mRNA platform.
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 ...
WEBApr 4, 2024 · Achilles is a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed...
Achilles Therapeutics Presents Encouraging Phase I/IIa Update on …
WEBLONDON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today presented an encouraging interim Phase I/IIa update on the use of clonal neoantigen reactive T cells (cNeT) from the CHIRON study in …
Achilles Therapeutics ADRs Rise 32% on Cost-Cutting Measures
WEB22 hours ago · American depositary receipts of Achilles Therapeutics rose 32% after the company disclosed cost-cutting measures as part of a strategic update.
Skip to content